SHAHEED RAJAIE CARDIOVASCULAR MEDICAL CENTER, MELLAT PARK, VALI-ASR AVE., TEHRAN, IRAN
Abstract
Objective- This randomized, double blind trial was designed to compare the efficacy and safety of ezetimibe, a new cholesterol-lowering agent with atorvastatin (Lipitor), a potent cholesterol inhibitor derivative. Method- Between September 2004 and March 2005, a total of 120 hyperlipidemic patients, aged 28-80 years, were randomized to receive ezetimibe 10 mg or atorvastatin 10 mg orally daily for 8 weeks after a 4-week washout phase and diet on NCEP step n. Mean changes of serum lipoproteins after 4 and 8 weeks of drug therapy were measured and compared in both groups of patients. Results- Ezetimibe reduced LDLc and total cholesterol by a mean of 27% and 16% compared with 32% and 24% for atorvastatin, respectively. The difference was not statistically significant. Conclusion- Ezetimibe and atorvastatin both reduced LDLc and TC with no statistically significant difference.
MOMTAHEN, M., FARSAD, F., ABAS, M., MOMTAHAN, S. & KAZAZI, A. (2007). DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. Iranian Heart Journal, 8(1), 33–37.
MLA
MOMTAHEN, M., FARSAD, F., ABAS, M., MOMTAHAN, S., & KAZAZI, A. "DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA", Iranian Heart Journal, 8, 1, 2007, 33–37.
HARVARD
MOMTAHEN, M., FARSAD, F., ABAS, M., MOMTAHAN, S., & KAZAZI, A. (2007). 'DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA', Iranian Heart Journal, 8(1), pp. 33–37.
CHICAGO
MOMTAHEN, M., FARSAD, F., ABAS, M., MOMTAHAN, S. & KAZAZI, A., "DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA." Iranian Heart Journal, 8 1 (2007): 33–37,
VANCOUVER
MOMTAHEN M., FARSAD F., ABAS M., MOMTAHAN S., KAZAZI A. DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. Iranian Heart Journal. 2007;8(1):33–37.
